Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

Relay Therapeutics

Key Facts as at 30.09.2025

Company locationUSA
Size in % of securities1.60%
Size of stake in company4.80%
Market capitalizationUSD 900 mn

Sector

Oncology

Main candidate

RLY-2608

Main indications

PI3Kα mutant metastatic breast cancer

About the company

Relay Therapeutics is a clinical-stage precision medicines company transforming the drug discovery process with the goal of bringing life-changing therapies to patients. Built on unparalleled insights into protein motion and how this dynamic behavior relates to protein function, Relay Therapeutics aims to effectively drug protein targets that have previously been intractable, with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company’s Dynamo platform integrates an array of leading-edge experimental and computational approaches to provide a differentiated understanding of protein structure and motion to drug these targets. The company has deployed its Dynamo platform to initially focus on the area of precision oncology. Most advanced clinical candidate is RLY-2608, a pan PI3Kα for the treatment of metastatic breast cancer with a PI3Kα mutation currently in Phase I/II dose expansion in combination with Standard of care.

Disclaimer

All comments as at December 31, 2024 or beginning of investment.

Any reference to a particular company or security does not constitute a recommendation to buy, sell, hold or directly invest in that company or security.